Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma.

NCT01425801 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01425801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01425801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2011
Completion date
February 1, 2012
Enrollment
62 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

asthma